Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End TB

Journal Article
  • Jan-Willem C. Alffenaar
  • Tawanda Gumbo
  • Kelly E. Dooley
  • Charles A. Peloquin
  • Helen McIlleron
  • Andre Zagorski
  • Daniela M. Cirillo
  • Scott K. Heysell
  • Denise Rossato Silva
  • Giovanni Battista Migliori
Clinical Infectious Diseases
2019. DOI: 10.1093/cid/ciz942.

Abstract

Tuberculosis (TB) elimination requires innovative approaches. The new Global Tuberculosis Network (GTN) aims to conduct research on key unmet therapeutic and diagnostic needs in the field of TB elimination using multidisciplinary, multisectorial approaches. The TB Pharmacology section within the new GTN aims to detect and study the current knowledge gaps, test potential solutions using human pharmacokinetics informed through preclinical infection systems, and return those findings to the bedside. Moreover, this approach would allow prospective identification and validation of optimal shorter therapeutic durations with new regimens. Optimized treatment using available and repurposed drugs may have an increased impact when prioritizing a person-centered approach and acknowledge the importance of age, gender, comorbidities, and both social and programmatic environments. In this viewpoint article, we present an in-depth discussion on how TB pharmacology and the related strategies will contribute to TB elimination.